{"filings":[{"id":1111998,"accession_number":"0001104659-26-075172","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-06-17T20:30:24+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Certara CFO John Gallagher resigns; Faiz Mohammed named Interim CFO; FY2026 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Gallagher resigns as CFO effective July 14, 2026 to pursue another opportunity; no disagreement with management.","Company launches search for permanent CFO with a leading executive search firm.","Faiz Mohammed, SVP Finance & Treasurer since 2018, appointed Interim CFO effective July 15, 2026.","Certara reaffirms FY2026 financial guidance provided on May 11, 2026 first-quarter earnings call.","Mohammed has over 25 years of finance and accounting experience, including public and private equity-backed companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471718,"accession_number":"0001104659-26-062640","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-05-15T20:31:48+00:00","items":["5.07"],"status":"ready","headline":"Certara stockholders elect directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three Class III directors elected: Bedi 121.7M for, McLean 99.9M for (22.9M withheld), Resnick 121.7M for.","RSM US LLP ratified as independent auditor for FY 2026: 141.7M for, 0.76M against.","Non-binding say-on-pay approved: 120.3M for, 2.3M against, 0.11M abstain.","Notable: ~22.9M shares withheld from director McLean, indicating shareholder dissent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95900,"accession_number":"0001827090-26-000017","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-05-11T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $106.9M (+1% YoY); software revenue $49.7M (+7%), services revenue $57.2M (-4%).","Net loss $8.8M vs net income $4.7M YoY; adjusted EBITDA $31.7M (-9% YoY); diluted EPS -$0.06 vs +$0.03.","Closed sale of Regulatory Writing/Medical Writing business to Veristat on May 8 for $85M cash + $15M escrow + up to $35M earn-out.","Updated 2026 guidance: revenue growth 0-4% excluding the divested business; software bookings up 20% to $48.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":106915000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95899,"accession_number":"0001104659-26-046358","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Certara sells Regulatory & Medical Writing business to Veristat for up to $135M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $100M plus up to $35M earn-out based on future performance.","Sold business generated $50M revenue and $17M adjusted EBITDA in 2025, employing ~220 people.","Transaction expected to close in Q2 2026 subject to customary conditions.","Certara will update 2026 guidance after close; proceeds to be deployed for MIDD platform growth.","Sale sharpens focus on Model-Informed Drug Development and AI-integrated modeling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109318,"accession_number":"0001104659-26-037798","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Cynthia Collins resigns from Certara board, effective May 14, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cynthia Collins notified her resignation as Class II director and Audit Committee member, effective at the 2026 annual meeting.","Resignation not due to any disagreement with the company on operations, policies, or practices.","Board will reduce to nine members after her departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109317,"accession_number":"0001827090-26-000008","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q4 revenue $103.6M (+3%), net loss $5.9M; appoints Jon Resnick CEO; FY26 rev growth 0-4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $103.6M (+3% YoY); software revenue $46.4M (+10%), services $57.3M (-1%).","Q4 net loss $5.9M vs net income $6.6M in Q4 2024; adj. EBITDA $32.5M (-3% YoY).","FY 2025 revenue $418.8M (+9%); adj. EBITDA $134.5M (+10%) with 32% margin.","FY 2026 guidance: revenue growth 0-4%, adj. EBITDA margin 30-32%, adj. diluted EPS $0.44-$0.48.","Jon Resnick appointed CEO and board member effective January 1, 2026, succeeding previous CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":418838000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125803,"accession_number":"0001104659-25-120096","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints Jon Resnick as CEO effective Jan 1, 2026; Feehery departs Dec 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Resnick, former IQVIA US/Canada President, named CEO effective Jan 1, 2026; William Feehery steps down Dec 31, 2025.","Resnick receives $750k base salary, 100% target bonus, $6.5M make-whole RSU, and LTI awards of $4M (2025) and $8M (2026).","Feehery to serve as external advisor at $20k/month consulting fee; post-employment benefits per existing agreement.","Resnick appointed as Class III director with term expiring at 2026 annual meeting.","Company reaffirms full year 2025 financial outlook as disclosed Nov 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125802,"accession_number":"0001827090-25-000046","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 2025 revenue $104.6M (+10% YoY); net income $1.5M vs loss; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $104.6M, +10% YoY; software $43.8M (+22%), services $60.8M (+3%).","Net income $1.5M vs net loss $1.4M in Q3 2024; adjusted EBITDA $35.2M (+7%).","Full-year 2025 guidance updated: profitability targets raised, revenue range narrowed.","Launched new software CertaraIQ for QSP modeling to expand biosimulation use.","CFO noted spending hesitancy in some services but strong QSP demand."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":315190000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125801,"accession_number":"0001104659-25-100106","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Certara refinances $296.25M term loans at lower interest rates","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sixth Amendment reduces margin on term loans to SOFR+2.75% or ABR+1.75%.","$296.25M Replacement Term Loans refinanced all existing term loans on Oct 16, 2025.","Expects reduced borrowing cost and interest expense savings versus prior terms.","All consenting lenders exchanged existing loans; one new lender joined.","Covenants, guarantees, and collateral terms remain substantially unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142534,"accession_number":"0001827090-25-000034","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).","Net loss improved 84% to $2.0M from $12.6M in Q2 2024.","Adjusted EBITDA $31.9M (+21% YoY); Chemaxon contributed $5.3M to revenue.","Full-year 2025 financial guidance reaffirmed, citing sustained demand for model-informed drug development.","CEO highlighted software product enhancements and new product introductions driving long-term growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":210574000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160581,"accession_number":"0001104659-25-052027","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Certara shareholders elect four Class II directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors elected: Eran Broshy (101.4M for, 44.5M withheld), Cynthia Collins (135.1M for), John Reynders (145.5M for), Matthew Walsh (131.7M for).","Ratified RSM US LLP as auditor for FY2025 with 150.4M for, 335.7K against, 83.1K abstain.","Advisory say-on-pay proposal approved with 139.1M for, 6.7M against, 81.7K abstain, 4.9M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160580,"accession_number":"0001827090-25-000026","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).","Net income $4.7M vs net loss of $4.7M in Q1 2024; adjusted EBITDA $34.8M (+20%).","Reiterated full-year 2025 financial guidance.","CEO cites FDA roadmap for reducing animal testing as opportunity for biosimulation.","CFO notes strong commercial execution despite biopharma headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":106004000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160579,"accession_number":"0001827090-25-000021","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Certara reports Q1 preliminary revenue up 10% to $106M; $100M buyback authorized","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 revenue $106.0M (+10% YoY); software revenue $46.4M (+18%), services $59.6M (+4%).","Bookings of $118.0M (+12% YoY); software bookings $40.6M (+22%), services bookings $77.4M (+7%).","Adjusted EBITDA estimated $33-$35M (13-20% growth); FY 2025 guidance reaffirmed: rev $415-$425M, adj EPS $0.42-$0.46.","Board authorized $100M share repurchase program; Arsenal Capital agrees to one-year lock-up on shares acquired from EQT.","Regulatory services strategic review ongoing; discussions with external parties remain preliminary."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":106004000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178826,"accession_number":"0001827090-25-000018","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Certara President Patrick F. Smith steps down, moves to senior advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025.","Smith remains employed at Certara in a senior advisory and scientific capacity.","No replacement for the President role was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178825,"accession_number":"0001827090-25-000012","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q4 revenue +14% to $100.4M; net income turns positive; guides 2025 margins","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $100.4M (+14% YoY); software rev $42.3M (+26%), services $58.1M (+7%).","Net income $6.6M vs net loss $12.5M in Q4 2023; adjusted EBITDA $33.5M (+13%).","Chemaxon contributed $6.6M revenue in Q4, ahead of expectations.","FY 2025 guidance: adj. EBITDA margins in low thirties; end markets similar to 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":385148000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178824,"accession_number":"0001827090-25-000003","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara reports preliminary Q4 revenue $99.7M (+13% YoY); FY revenue $384.4M (+8%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $99.7M vs $88.0M YoY; software +24% to $41.6M, services +7% to $58.1M.","FY 2024 revenue $384.4M vs $354.3M; software +18% to $155.0M, services +3% to $229.4M.","Full-year bookings $445.3M (+11% YoY); adjusted EBITDA guidance reaffirmed at $120M-$124M.","Q4 bookings $144.5M (+22% YoY); included Chemaxon contribution of $5.9M revenue and $11.0M bookings.","Chemaxon acquisition closed Oct 1, 2024; prelim results are unaudited and subject to finalization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":385148000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195497,"accession_number":"0001827090-24-000035","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 rev $94.8M (+11% YoY); net loss narrows to $1.4M; guides FY24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $94.8M (+11% YoY); software rev $35.9M (+15%), services rev $58.9M (+9%).","Net loss $1.4M vs $49.0M loss in Q3 2023; improvement driven by lower goodwill impairment.","Adjusted EBITDA $33.1M, up 15% from $28.8M in Q3 2023.","CEO cites Chemaxon acquisition closed; focus on integrating biosimulation platform.","Full-year 2024 financial guidance updated (specifics not provided in release snippet)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":284787000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195496,"accession_number":"0001104659-24-109235","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints Dr. John V. W. Reynders to Board of Directors, effective Oct 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Reynders appointed as Class II director and Audit Committee member, effective immediately.","Board size increased from 9 to 10 directors.","Compensation per non-employee director policy; standard indemnification agreement to be entered.","No family relationships or transactions with officers/directors requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211759,"accession_number":"0001827090-24-000028","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 2024 revenue $93.3M (+3% YoY); net loss $12.6M vs profit prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $93.3M, up 3% YoY; software revenue $38.2M (+13%), services revenue $55.1M (-3%).","Net loss $12.6M compared to net income $4.7M in Q2 2023; adjusted EBITDA $26.3M vs $32.4M prior year.","Company reiterates full-year 2024 financial guidance.","CEO cites strong software performance offset by slowing large biopharma services demand."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":189967000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211758,"accession_number":"0001104659-24-081169","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Certara amends bylaws to remove former majority stockholder provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["On July 17, 2024, Board approved amended and restated Bylaws, effective same day.","Changes remove inoperative provisions related to former majority stockholder.","Certificate of Incorporation similarly amended; stockholder approval on May 23, 2024.","Full text of Bylaws filed as Exhibit 3.2, marked changes as Exhibit 3.3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211757,"accession_number":"0001104659-24-078581","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.","Transaction expected to close in H2 2024, subject to regulatory approval and customary conditions.","Chemaxon expected to generate >$20M software revenue in 2024; adjusted EBITDA margin near Certara's corporate average by end 2025.","Certara reiterates 2024 revenue, adjusted EBITDA margin (31-33%), and adjusted diluted EPS guidance from May 7 earnings call.","Acquisition expands Certara's drug discovery biosimulation portfolio; long-term partnership with Chemaxon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230508,"accession_number":"0001104659-24-075179","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Certara refinances credit facility; extends term loan maturity to 2031, revolver to 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total new term loans of $300M (including $5M incremental) refinance existing debt and fund general corporate purposes.","Term loan maturity extended to June 26, 2031; revolving facility maturity extended to June 26, 2029.","Pricing reduced: Term SOFR + 3.00% for term loans; revolver spread 2.75%-3.50% based on leverage.","New term loans funded at 99.75% of par (0.25% original issue discount).","Company expects interest expense savings compared to prior credit agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230507,"accession_number":"0001827090-24-000018","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Certara shareholders elect directors, approve charter amendments, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class I directors: Cashman (97.7M for), Killefer (116.4M), Spaight (134.1M); all supported.","Approved charter amendment to limit officer liability (121.99M for, 17.85M against).","Approved technical charter amendments (139.78M for, 62.6K against).","Ratified Ernst & Young as auditor for FY2024 (143.94M for).","Advisory vote on executive compensation passed (132.6M for, 7.23M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230506,"accession_number":"0001827090-24-000011","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 revenue $96.7M +7% YoY; net loss $4.7M, reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $96.7M (+7% YoY); software rev $39.3M (+19%), services $57.3M (flat).","Net loss $4.7M vs net income $1.4M in Q1 2023; adjusted EBITDA $29.1M down from $32.3M.","Software net retention ratio 114%.","Reiterated full year 2024 financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":96654000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248893,"accession_number":"0001827090-24-000005","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q4 revenue $88M (+2% YoY); net loss of $12.5M vs $9.2M income in prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss includes $12.8M increase in fair value of contingent consideration remeasurement related to Vyasa Analytics.","Adjusted EBITDA was $29.6M, down from $31.9M in Q4 2022.","Record software bookings and broad-based recovery in technology-enabled services bookings in the quarter.","Full year 2024 financial guidance provided; CEO cites improved execution and investment in AI capabilities.","Total revenue $88.0M for Q4 2023 vs $86.6M in prior year; constant-currency growth 1%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":354337000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266427,"accession_number":"0001827090-23-000018","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 revenue up 1% to $85.6M; net loss $49.0M on $47M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $85.6M (+1% YoY); regulatory revenue declined but biosimulation demand stable.","Net loss $49.0M vs net income $3.9M in Q3 2022; includes $47.0M goodwill impairment in Regulatory business.","Adjusted EBITDA $28.8M vs $32.7M YoY; adjusted net income $17.1M vs $16.6M YoY.","Reiterates full year 2023 guidance; bookings recovery in services and strong software pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":266327000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283661,"accession_number":"0001827090-23-000008","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 revenue $90.5M, net income $4.7M; lowers FY2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $90.5M (+9% YoY, +10% constant currency); net income $4.7M vs loss $0.6M.","Adjusted EBITDA $32.4M (+16% YoY); software revenue and bookings each +17% YoY.","Services revenue +5% YoY but bookings declined; CEO cites cautious spending by small biotech.","Software renewal rate 93% in Q2; management expects services demand improvement in 2024.","FY2023 full-year guidance reduced due to lower services growth and slow regulatory recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":180751000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303191,"accession_number":"0001558370-23-010467","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Certara shareholders elect three directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected William Feehery, Rosemary Crane, and Stephen McLean as Class III directors with 130.4M, 133.1M, and 104.9M for votes respectively.","Ratified independent registered public accounting firm for FY2023 with 139.5M for votes vs 12.9K against.","Advisory vote on named executive officer compensation approved with 131.5M for votes vs 3.5M against.","Broker non-votes were 4.4M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303190,"accession_number":"0001558370-23-008534","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 revenue $90.3M (+11% YoY); net income $1.4M, down 39%; reiterates 2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $90.3M, up 11% YoY (13% constant currency); net income $1.4M, down 39% vs Q1 2022.","Adjusted EBITDA $32.3M, up 17% YoY; management cites healthy bookings and strong balance sheet.","Reiterates full-year 2023 financial guidance; added to S&P SmallCap 600 index effective March 22, 2023.","Software and biosimulation services drove growth; negative FX impact partially offset sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":90301000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322832,"accession_number":"0001558370-23-005306","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara modifies 2022 PSU targets; caps maximum payout at 100% for 2023-2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Compensation Committee modified 2022 PSU award agreements for all participants including CEO, CFO, and NEOs.","For fiscal 2023-2024, target revenue/FCF growth remains 20% if acquisition contributes >5% growth; otherwise reverts to 15%.","Maximum Weighted Percentage for entire performance period capped at 100%, eliminating above-target payout.","Change intended to align performance goals with expected growth rates and provide flexibility for future acquisitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322831,"accession_number":"0001558370-23-002580","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara reports Q4 revenue $86.6M (+15% YoY); net income $9.2M vs loss year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $86.6M, up 15% reported (18% constant currency) from $75.3M in Q4 2021.","Q4 net income $9.2M vs net loss $9.7M in Q4 2021; adjusted EBITDA $31.9M (+13%).","Full year 2022 revenue $335.6M (+17% reported, +20% constant currency); net income $14.7M vs loss $13.3M in 2021.","Full year adjusted EBITDA $120.2M, up 16% from $103.7M in 2021.","Acquired Vyasa Analytics, an AI company with scalable deep-learning software; 2023 guidance issued."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":335644000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322830,"accession_number":"0001104659-23-027320","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints John Gallagher as CFO effective April 1, 2023; Schemick transitions to new role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Gallagher named CFO, effective April 1, 2023, succeeding Andrew Schemick.","Schemick becomes SVP, Corporate Operations and Integration, focusing on operational excellence.","Gallagher previously CFO of Cue Health; held senior roles at BD, GE, and Ford.","Gallagher receives base salary of $575,000, 50% bonus target, $200,000 signing bonus, and $2.75M equity awards.","Equity includes $1.26M performance stock units, $840K and $650K restricted stock units with multi-year vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340893,"accession_number":"0001558370-22-018972","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara director Mason Slaine resigns, effective December 23, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mason Slaine resigned from the Board for personal reasons, effective Dec 23, 2022.","Resignation not the result of any disagreement with the Company on operations, policies, or practices.","Slaine served on the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340892,"accession_number":"0001104659-22-125493","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Certara announces $449M stock purchase by Arsenal Capital Partners at $15/share; David Spaight joins board","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Arsenal Capital Partners closed $449M purchase of 29,954,521 shares from EQT at $15.00/share.","David Spaight appointed to Board; Eric Liu and Ethan Waxman resign (EQT representatives).","Arsenal agreed to two-year lock-up on new shares, signaling long-term commitment.","Stephen McLean remains on Board; moves to Nominating and Corporate Governance Committee from Audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340891,"accession_number":"0001558370-22-016622","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 revenue up 15% to $84.7M; Arsenal to acquire EQT's 30M shares at $15/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $84.7M (+15% YoY); net income $3.9M vs loss $1.8M; adjusted EBITDA $32.7M (+25%).","Reiterated full-year 2022 guidance; constant-currency revenue growth 18%.","Organic revenue (ex-Pinnacle 21) grew 4% reported, 8% constant currency.","Arsenal Investment Partners to acquire EQT's 30M shares at $15/share; two-year lock-up, board seats."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":249011000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340890,"accession_number":"0001104659-22-115148","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Arsenal Capital Partners commits $449M to buy ~30M Certara shares at $15/sh; expects 22% ownership","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Arsenal will acquire ~30M shares from EQT at $15/share, total $449M; subject to HSR regulatory approval.","Post-closing, Arsenal will own ~22% of diluted shares; currently holds ~4%.","Arsenal agrees to two-year lock-up on sale of purchased shares without company approval.","Arsenal to nominate two board members: Steve McLean (current) and David Spaight; EQT's Liu and Waxman to resign.","Board will expand to 11 members; Stockholders Agreement grants Arsenal director nomination rights based on ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358044,"accession_number":"0001104659-22-091341","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Certara enters underwriting agreement for secondary offering of 7M shares by selling stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7,000,000 shares of common stock offered by selling stockholders; underwriters have 30-day option for 1,050,000 additional shares.","Company will not receive any proceeds from the offering; all shares are sold by existing stockholders.","Offering expected to close on August 16, 2022, subject to customary conditions.","Underwriting agreement with Morgan Stanley & Co. LLC as sole underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358043,"accession_number":"0001558370-22-013532","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara announces resignation of President of Regulatory and Access Justin Edge, effective Sept 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Edge, President of Regulatory and Access, resigned effective September 1, 2022.","No replacement has been announced as of the filing date.","Edge's departure is a senior leadership change at the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358042,"accession_number":"0001558370-22-012883","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 revenue $82.8M (+18% YoY); guides FY22 lower on FX, regulatory softness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $82.8M, up 18% reported or 21% constant currency; excluding Pinnacle 21, up 8% reported.","Net loss improved to $0.6M from $2.9M in Q2 2021; Adjusted EBITDA $28.0M (+9% YoY).","FY 2022 guidance adjusted lower for FX headwinds and slow regulatory services recovery.","Biosimulation revenue and bookings grew double-digit; two new software products launched.","CFO expects FX and regulatory services softness to continue in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":164311000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358041,"accession_number":"0001558370-22-010938","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara appoints Rosemary A. Crane to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 11 members, creating a new Class III vacancy.","Rosemary A. Crane elected as Class III director effective July 21, 2022.","Crane appointed to Compensation Committee; will receive standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358040,"accession_number":"0001558370-22-010661","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-07-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Certara expands board to 10, appoints Eran Broshy as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 9 to 10 members effective July 11, 2022.","Elected Eran Broshy as a Class III director, effective July 11, 2022.","Broshy appointed to Audit Committee; will receive standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376755,"accession_number":"0001558370-22-009195","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Certara elects directors; Eric C. Liu receives 22.4M withhold votes; auditor ratified; say-on-pay 1 year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class II directors elected: Cynthia Collin, Eric C. Liu, Matthew M. Walsh to serve until 2025.","Eric C. Liu received 22.4M withhold votes (18% of votes cast), a notable protest level.","Ratification of Deloitte & Touche as FY2022 auditor passed: 126.6M for, 2.7K against.","Advisory vote on say-on-pay frequency: overwhelming support for 1 year (122.6M votes), board will consider."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376754,"accession_number":"0001558370-22-007383","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q1 revenue $81.6M (+22% YoY), net income $2.2M, adj EBITDA $27.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $81.6M, up 22% YoY; excluding Pinnacle 21, up 13% to $75.6M.","Net income $2.2M (up 110% YoY); diluted EPS $0.01, flat YoY.","Adjusted EBITDA $27.7M, up 16% YoY from $23.9M.","Management reaffirms 2022 outlook for mid-teens revenue growth amid strong demand."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":81551000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376753,"accession_number":"0001558370-22-005137","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Carol Gallagher resigns from Certara board effective April 5, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Carol Gallagher resigned for personal reasons, effective April 5, 2022.","Resignation is not due to any disagreement with Certara's operations, policies, or practices.","Board size reduced from ten to nine directors.","Gallagher had served as Chair of the Compensation Committee and member of the Nominating and Corporate Governance Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395113,"accession_number":"0001558370-22-004739","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Certara dismisses auditor CohnReznick, engages RSM after adverse internal control opinion for FY2021","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved dismissal of CohnReznick effective upon filing Q1 2022 10-Q; RSM engaged for FY2022 subject to acceptance.","CohnReznick's audit reports for FY2021 and FY2020 were unqualified except for change in lease accounting (ASC 842).","Reportable event: CohnReznick issued adverse opinion on internal control over financial reporting for FY2021 due to material weakness.","Material weakness involved IT general controls over cloud-based software for project setup and customer time submissions.","No disagreements on accounting principles or audit scope; material weakness was discussed with Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395112,"accession_number":"0001558370-22-002598","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2022-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara reports Q4 revenue $75.3M (+17% YoY), net loss narrows to $9.7M from $54.5M; updates 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $75.3M, up 17% YoY; net loss $9.7M vs $54.5M loss in Q4 2020.","Adjusted EBITDA $28.2M, up 27% from $22.2M; diluted loss per share ($0.06) vs ($0.40).","Full year 2021 revenue $286.1M (+17% YoY); net loss $13.3M vs $49.4M loss in 2020.","Software revenue ex-Pinnacle 21 grew 13% YoY; technology-driven services grew 6% in Q4.","Pinnacle 21 acquisition contributed $6.1M revenue in Q4; management issued updated 2022 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":286104000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413808,"accession_number":"0001558370-21-015291","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q3 revenue $73.9M (+23% YoY), raises FY21 guidance, acquires Pinnacle 21 for $250M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $73.9M, up 23% YoY; net loss $1.8M vs net income $1.2M in Q3 2020.","Adjusted EBITDA $26.1M (+28% YoY); diluted EPS ($0.01) vs $0.01.","Acquired Pinnacle 21 for $250M cash plus 2,239,717 restricted shares, closed Oct 1, 2021.","Raised 2021 guidance: GAAP revenue $288-291M, adjusted EBITDA $106-108M, adjusted diluted EPS $0.22-0.26."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":210758000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413807,"accession_number":"0001104659-21-122284","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2021-10-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Certara completes $310M acquisition of Pinnacle 21, a clinical data compliance SaaS provider","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value $310M; ~$250M cash + 2,239,717 restricted shares to equityholders.","Pinnacle 21 software validates CDISC compliance required by FDA and PMDA.","Transaction expected to be accretive to Certara's revenue, growth, and adjusted EBITDA.","Pinnacle 21 used by FDA, PMDA, and 22 of top 25 biopharma R&D spenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432248,"accession_number":"0001558370-21-010588","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Certara Q2 revenue $70.1M (+15% YoY); acquires Pinnacle 21 for $310M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $70.1M, +15% YoY; net loss $2.9M vs net income $2.8M in Q2 2020.","Adjusted EBITDA $25.5M, +1% YoY; diluted EPS $(0.02) vs $0.02 prior year.","Announced acquisition of Pinnacle 21 for $310M in cash/stock; closing expected early Q4 2021.","Raised FY2021 guidance: revenue $283-289M, Adj EBITDA $101-103M, Adj diluted EPS $0.21-0.25."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":136814000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432247,"accession_number":"0001104659-21-100776","cik":1827090,"company_name":"Certara, Inc.","ticker":"CERT","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Certara acquires Pinnacle 21 for $310M in cash and stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Enterprise value $310M: $250M cash + $60M in newly issued Certara shares.","Acquisition expected to be immediately accretive to revenue, revenue growth, and adjusted EBITDA margin.","Pinnacle 21 provides FDA/PMDA-required clinical data standardization software; 22 of top 25 pharma companies are customers.","Transaction unanimously approved; expected to close early Q4 2021 subject to regulatory approvals.","Deal expands Certara's biosimulation platform into data fitness and regulatory software."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":878551095.3897196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-05T23:59:59+00:00|432247"}